About: covid:1ae81b9644b11b1a871428c67d91bb67a592b5a5

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:1ae81b9644b11b1a871428c67d91bb67a592b5a5 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Felton, Timothy Hites, Maya Roberts, Jason De Cock, Pieter Koch, Birgit Le, Jennifer Macgowan, Alasdair Luque, Sonia Muller, E Zeitlinger, Markus Anouk, · Bruggemann, · Deborah, · Marriott, J
is schema:about of	named entity 'anticipated' named entity 'LPV' named entity 'favipiravir' named entity 'therapies' named entity 'post-exposure prophylaxis' named entity 'Pharmacokinetics' named entity 'Interaction' named entity 'Clinical Microbiology' named entity '283' named entity 'TREATING' named entity 'FOCUSING' named entity 'uncertainty' named entity 'pharmacokinetics' named entity 'pharmacological' named entity 'pharmacology' named entity 'Middle East Respiratory Syndrome' named entity 'data' named entity 'strong' named entity 'drugs' named entity 'Antiviral' named entity 'antiviral therapies' named entity 'healthcare workers' named entity 'chloroquine' named entity 'drug interactions' named entity 'pharmacological' named entity 'LPV' named entity 'antiviral therapies' named entity 'remdesivir' named entity 'pharmacology' named entity 'DDIs' named entity 'Infectious Diseases' named entity 'Clinical Microbiology' named entity 'PK/PD' named entity 'ribavirin' named entity 'SIRS' named entity 'SARS-CoV' named entity 'COVID-19' named entity 'oxygenator' named entity 'HIV protease inhibitor' named entity 'global pandemic' named entity 'COVID-19' named entity 'combination therapies' named entity 'excreted' named entity 'long-term' named entity 'antiviral' named entity 'ARDS' named entity 'QTc prolongation' named entity 'MERS' named entity 'COVID' named entity 'University of Liverpool' named entity 'cell culture' named entity 'SARS-CoV-2' named entity 'IHD' named entity 'dexamethasone' named entity 'handwashing' named entity 'COVID' named entity 'antiretrovirals' named entity 'infection' named entity 'RNA' named entity 'physicochemical properties' named entity 'drug therapies' named entity 'standard of care' named entity 'DDIs' named entity 'oxygenator' named entity 'hydroxychloroquine' named entity 'SARS-CoV-2' named entity 'single-agent' named entity 'ribavirin' named entity 'RRT' named entity 'LPV' named entity 'critically ill patients' named entity 'ventilation support' named entity 'remdesivir' named entity 'antiviral' named entity 'inoculum' named entity 'COVID' named entity 'infection' named entity 'viral shedding' named entity 'LPV' named entity 'preclinically' named entity 'Randomized trials' named entity 'CYP3A4' named entity '28 days' named entity 'adaptive design' named entity 'hydroxychloroquine' named entity 'antiretroviral drugs'

Attributes

Values

Creator

Felton, Timothy
Hites, Maya
Roberts, Jason
De Cock, Pieter
Koch, Birgit
Le, Jennifer
Macgowan, Alasdair
Luque, Sonia
Muller, E
Zeitlinger, Markus
Anouk, ·
Bruggemann, ·
Deborah, ·
Marriott, J

is schema:about of

named entity 'anticipated'
named entity 'LPV'
named entity 'favipiravir'
named entity 'therapies'
named entity 'post-exposure prophylaxis'
named entity 'Pharmacokinetics'
named entity 'Interaction'
named entity 'Clinical Microbiology'
named entity '283'
named entity 'TREATING'
named entity 'FOCUSING'
named entity 'uncertainty'
named entity 'pharmacokinetics'
named entity 'pharmacological'
named entity 'pharmacology'
named entity 'Middle East Respiratory Syndrome'
named entity 'data'
named entity 'strong'
named entity 'drugs'
named entity 'Antiviral'
named entity 'antiviral therapies'
named entity 'healthcare workers'
named entity 'chloroquine'
named entity 'drug interactions'
named entity 'pharmacological'
named entity 'LPV'
named entity 'antiviral therapies'
named entity 'remdesivir'
named entity 'pharmacology'
named entity 'DDIs'
named entity 'Infectious Diseases'
named entity 'Clinical Microbiology'
named entity 'PK/PD'
named entity 'ribavirin'
named entity 'SIRS'
named entity 'SARS-CoV'
named entity 'COVID-19'
named entity 'oxygenator'
named entity 'HIV protease inhibitor'
named entity 'global pandemic'
named entity 'COVID-19'
named entity 'combination therapies'
named entity 'excreted'
named entity 'long-term'
named entity 'antiviral'
named entity 'ARDS'
named entity 'QTc prolongation'
named entity 'MERS'
named entity 'COVID'
named entity 'University of Liverpool'
named entity 'cell culture'
named entity 'SARS-CoV-2'
named entity 'IHD'
named entity 'dexamethasone'
named entity 'handwashing'
named entity 'COVID'
named entity 'antiretrovirals'
named entity 'infection'
named entity 'RNA'
named entity 'physicochemical properties'
named entity 'drug therapies'
named entity 'standard of care'
named entity 'DDIs'
named entity 'oxygenator'
named entity 'hydroxychloroquine'
named entity 'SARS-CoV-2'
named entity 'single-agent'
named entity 'ribavirin'
named entity 'RRT'
named entity 'LPV'
named entity 'critically ill patients'
named entity 'ventilation support'
named entity 'remdesivir'
named entity 'antiviral'
named entity 'inoculum'
named entity 'COVID'
named entity 'infection'
named entity 'viral shedding'
named entity 'LPV'
named entity 'preclinically'
named entity 'Randomized trials'
named entity 'CYP3A4'
named entity '28 days'
named entity 'adaptive design'
named entity 'hydroxychloroquine'
named entity 'antiretroviral drugs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software